Comment on 'Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial' by Tanaka et al.
Lea C BerkhoutMerel J l'AmiGerrit Jan WolbinkTheo RispensPublished in: Annals of the rheumatic diseases (2019)